Scarica l'app Stockscreener
10.10
8.55%
0.86
Precedente Chiudi:
$9.24
Aprire:
$9.28
Volume 24 ore:
167.05K
Relative Volume:
1.93
Capitalizzazione di mercato:
$50.16M
Reddito:
$34.77M
Utile/perdita netta:
$-74.04M
Rapporto P/E:
-1.26
EPS:
-8.0157
Flusso di cassa netto:
$-79.76M
1 W Prestazione:
+22.32%
1M Prestazione:
+40.48%
6M Prestazione:
+29.04%
1 anno Prestazione:
-79.63%
Intervallo 1D:
$9.24
$10.32
Intervallo di 1 settimana:
$7.8275
$10.32
Portata 52W:
$5.21
$70.75
Mersana Therapeutics Inc Stock (MRSN) Company Profile
Nome
Mersana Therapeutics Inc
Settore
Industria
Telefono
617-498-0020
Indirizzo
840 MEMORIAL DRIVE, CAMBRIDGE
Confronta MRSN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRSN
Mersana Therapeutics Inc
|
10.05 | 46.11M | 34.77M | -74.04M | -79.76M | -8.0157 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.60 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
472.80 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.08 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
801.50 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
330.08 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-06 | Iniziato | William Blair | Outperform |
| 2024-11-15 | Ripresa | Citigroup | Buy |
| 2024-03-19 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2024-02-29 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2024-02-29 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2024-02-29 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2023-12-04 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-07-28 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2023-07-27 | Downgrade | BTIG Research | Buy → Neutral |
| 2023-07-27 | Downgrade | Citigroup | Buy → Neutral |
| 2023-07-27 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-07-27 | Downgrade | JP Morgan | Neutral → Underweight |
| 2023-07-27 | Downgrade | Truist | Buy → Hold |
| 2023-07-27 | Downgrade | Wedbush | Outperform → Neutral |
| 2023-06-16 | Downgrade | JP Morgan | Overweight → Neutral |
| 2023-06-15 | Iniziato | Guggenheim | Buy |
| 2023-03-16 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-01-20 | Iniziato | Citigroup | Buy |
| 2022-11-21 | Iniziato | Truist | Buy |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2021-08-30 | Iniziato | H.C. Wainwright | Buy |
| 2021-03-31 | Iniziato | Credit Suisse | Neutral |
| 2020-12-03 | Iniziato | Stifel | Buy |
| 2020-09-29 | Ripresa | JP Morgan | Neutral |
| 2020-04-29 | Iniziato | BTIG Research | Buy |
| 2020-01-21 | Reiterato | H.C. Wainwright | Buy |
| 2019-03-11 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-11-14 | Aggiornamento | Leerink Partners | Mkt Perform → Outperform |
| 2018-05-08 | Iniziato | Robert W. Baird | Outperform |
| 2018-03-19 | Downgrade | JP Morgan | Overweight → Neutral |
Mostra tutto
Mersana Therapeutics Inc Borsa (MRSN) Ultime notizie
Why Mersana Therapeutics Inc. is moving todayJuly 2025 Macro Moves & High Accuracy Investment Signals - newser.com
Why Mersana Therapeutics Inc. stock remains a top recommendationTrade Signal Summary & Daily Momentum Trading Reports - newser.com
Is Mersana Therapeutics Inc. stock ready for a breakoutTrade Risk Assessment & AI Powered Market Entry Ideas - newser.com
Will Mersana Therapeutics Inc. stock beat EPS estimatesJuly 2025 Selloffs & Weekly High Return Stock Forecasts - newser.com
Risk adjusted return profile for Mersana Therapeutics Inc. analyzedJuly 2025 Institutional & Fast Momentum Stock Entry Tips - newser.com
How to track smart money flows in Mersana Therapeutics Inc.2025 Sector Review & Fast Moving Stock Watchlists - newser.com
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Is Mersana Therapeutics Inc. (0M4) stock supported by free cash flow2025 Top Decliners & AI Driven Price Predictions - newser.com
Mersana initiated at outperform at William Blair on antibody-drug conjugate potential - MSN
Does Mersana Therapeutics Inc. fit your quant trading modelFed Meeting & Safe Entry Zone Tips - newser.com
Relative strength of Mersana Therapeutics Inc. in sector analysis2025 Historical Comparison & Real-Time Stock Entry Alerts - newser.com
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Surges 26% Yet Its Low P/S Is No Reason For Excitement - simplywall.st
Mersana Therapeutics (NASDAQ:MRSN) Stock Price Down 3.9% – Should You Sell? - Defense World
What MACD and RSI say about Mersana Therapeutics Inc.2025 Geopolitical Influence & Long Hold Capital Preservation Plans - newser.com
Why Mersana Therapeutics Inc. (0M4) stock attracts HNW investors2025 Pullback Review & Expert Curated Trade Ideas - newser.com
What valuation multiples suggest for Mersana Therapeutics Inc. stockJobs Report & Verified Momentum Stock Ideas - newser.com
What MACD signals say about Mersana Therapeutics Inc.2025 Volatility Report & Safe Entry Momentum Tips - newser.com
Is Mersana Therapeutics Inc. stock bottoming outMarket Growth Report & Stepwise Trade Signal Implementation - newser.com
Is this a good reentry point in Mersana Therapeutics Inc.Short Setup & Daily Risk Controlled Trade Plans - newser.com
What drives Mersana Therapeutics Inc stock pricePrice Volatility Patterns & Build Winning Strategies With Zero Cost - earlytimes.in
How resilient is Mersana Therapeutics Inc. stock in market downturns2025 Major Catalysts & Community Verified Swing Trade Signals - newser.com
Pattern recognition hints at Mersana Therapeutics Inc. upsideJuly 2025 Update & Free Real-Time Market Sentiment Alerts - newser.com
Is Mersana Therapeutics Inc a good long term investment - earlytimes.in
How Mersana Therapeutics Inc. stock compares to industry benchmarks2025 Volume Leaders & AI Forecasted Entry and Exit Points - newser.com
Will a bounce in Mersana Therapeutics Inc. offer an exitEarnings Beat & AI Enhanced Execution Alerts - newser.com
How to use Fibonacci retracement on Mersana Therapeutics Inc.Breakout Watch & Comprehensive Market Scan Reports - newser.com
What technical models suggest about Mersana Therapeutics Inc.’s comebackJuly 2025 Catalysts & Weekly Chart Analysis and Guides - newser.com
Published on: 2025-10-03 01:27:08 - newser.com
Published on: 2025-10-02 20:29:11 - newser.com
Applying Wyckoff theory to Mersana Therapeutics Inc. stock2025 Market Sentiment & Free Community Supported Trade Ideas - newser.com
Mersana Therapeutics Inc Stock Analysis and ForecastVolume Profile Analysis & Fast Profit Investment Ideas - earlytimes.in
Mersana Therapeutics Inc Azioni (MRSN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Mersana Therapeutics Inc Azioni (MRSN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Huber Martin H. Jr. | President, CEO |
Sep 12 '25 |
Sale |
7.31 |
2,012 |
14,708 |
9,572 |
| Mandelia Ashish | VP, Chief Accounting Officer |
Jan 15 '25 |
Option Exercise |
0.00 |
8,685 |
0 |
61,073 |
| Mandelia Ashish | VP, Chief Accounting Officer |
Jan 16 '25 |
Sale |
0.58 |
3,554 |
2,061 |
57,519 |
| Protopapas Anna | Director |
Jan 15 '25 |
Option Exercise |
0.00 |
21,250 |
0 |
176,678 |
| Protopapas Anna | Director |
Jan 16 '25 |
Sale |
0.58 |
8,637 |
5,009 |
168,041 |
| Lowinger Timothy B | SVP, Chief Sci.&Tech. Officer |
Jan 15 '25 |
Option Exercise |
0.00 |
19,791 |
0 |
265,721 |
| Lowinger Timothy B | SVP, Chief Sci.&Tech. Officer |
Jan 16 '25 |
Sale |
0.58 |
8,048 |
4,668 |
257,673 |
| Huber Martin H. Jr. | President, CEO |
Jan 15 '25 |
Option Exercise |
0.00 |
11,062 |
0 |
127,389 |
| Huber Martin H. Jr. | President, CEO |
Jan 16 '25 |
Sale |
0.58 |
4,514 |
2,618 |
122,875 |
| DeSchuytner Brian | SVP, COO & CFO |
Jan 15 '25 |
Option Exercise |
0.00 |
20,833 |
0 |
129,863 |
1.24%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):